Literature DB >> 34222783

A case series of Brugada syndrome with a novel mutation in the ankyrin-B gene: an unusual unmasking in acute myocarditis.

Maria E Marketou1, Ilias Zareas2, Emmanuel Kanoupakis1, Alexandros Patrianakos1, Fragiskos Parthenakis1.   

Abstract

BACKGROUND: Brugada syndrome (BrS) is a genetically heterogeneous channelopathy that may lead to sudden death. We report a novel mutation of the ankyrin-B gene that is probably related to the occurrence of BrS in two brothers. CASE
SUMMARY: First, we present the case of a 27-year-old male who was admitted to the hospital with acute myocarditis. The patient showed left ventricular dysfunction and was given carvedilol. Six days later, while asymptomatic and afebrile, the patient exhibited an electrocardiogram (ECG) with repolarization 'saddleback' ST changes in V2. A procainamide provocative test was performed with a response for Type 1 Brugada ECG pattern. Genetic testing revealed a novel mutation, c.5418T>A (+/-) (p.His1806Gln), in the ankyrin-B gene encoding. His 34 years old brother had an ECG J point elevation in leads V1 and V2 of 1 mm not fulfilling diagnostic criteria for Brugada ECG pattern. He also experienced arrhythmia-related syncope. Flecainide provocation test changed ECG towards a Type 1 Brugada pattern. A subcutaneous implantable defibrillator (ICD) was implanted. Patient 1 remains asymptomatic while Patient 2 experienced an appropriate ICD shock during follow-up. DISCUSSION: In this case series, two brothers with BrS exhibited the same mutation of the ankyrin-B gene. Ankyrin-B is associated with the stability of plasma membrane proteins in the voltage-gated ion channels. Our finding provides a foundation for further investigation of this mutation in relation to BrS. Moreover, the timing of its presentation raises concerns as to whether myocarditis or beta-blockers are associated with the presentation of BrS ECG. © Crown copyright 2021.

Entities:  

Keywords:  Brugada syndrome; Case series; Electrophysiologic study; Mutation; Provocation test

Year:  2021        PMID: 34222783      PMCID: PMC8243220          DOI: 10.1093/ehjcr/ytab225

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


  17 in total

1.  Comparative study of carvedilol and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells.

Authors:  Rui Zhang; Ling-Jun Jie; Wei-Yin Wu; Zhi-Quan Wang; Hai-Ying Sun; Guo-Sheng Xiao; Yan Wang; Yi-Gang Li; Gui-Rong Li
Journal:  Eur J Pharmacol       Date:  2019-03-15       Impact factor: 4.432

2.  Effect of carvedilol on atrial excitation-contraction coupling, Ca2+ release, and arrhythmogenicity.

Authors:  E Martinez-Hernandez; L A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-04-10       Impact factor: 4.733

Review 3.  Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.

Authors:  Charles Antzelevitch; Pedro Brugada; Martin Borggrefe; Josep Brugada; Ramon Brugada; Domenico Corrado; Ihor Gussak; Herve LeMarec; Koonlawee Nademanee; Andres Ricardo Perez Riera; Wataru Shimizu; Eric Schulze-Bahr; Hanno Tan; Arthur Wilde
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

4.  Brugada-pattern electrocardiogram in propranolol intoxication.

Authors:  Stephen L Rennyson; Laszlo Littmann
Journal:  Am J Emerg Med       Date:  2010-02       Impact factor: 2.469

5.  Regulation of the ankyrin-B-based targeting pathway following myocardial infarction.

Authors:  Thomas J Hund; Patrick J Wright; Wen Dun; Jedidiah S Snyder; Penelope A Boyden; Peter J Mohler
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

6.  Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome.

Authors:  Dan Hu; Hector Barajas-Martínez; Ryan Pfeiffer; Fabio Dezi; Jenna Pfeiffer; Tapan Buch; Matthew J Betzenhauser; Luiz Belardinelli; Kristopher M Kahlig; Sridharan Rajamani; Harry J DeAntonio; Robert J Myerburg; Hiroyuki Ito; Pramod Deshmukh; Mark Marieb; Gi-Byoung Nam; Atul Bhatia; Can Hasdemir; Michel Haïssaguerre; Christian Veltmann; Rainer Schimpf; Martin Borggrefe; Sami Viskin; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

7.  2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).

Authors:  Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

8.  Fatal parvoviral myocarditis: a case report and review of literature.

Authors:  Fabio Tavora; Luis F Gonzalez-Cuyar; Jay S Dalal; Michael T O'Malley; Richard Zhao; Hong Q Peng; Allen P Burke
Journal:  Diagn Pathol       Date:  2008-04-30       Impact factor: 2.644

9.  Brugada syndrome in a young patient with type 1 myotonic dystrophy requiring an implantable cardioverter defibrillator for primary prevention: a case report.

Authors:  Panagiotis Korantzopoulos; Aris Bechlioulis; Lampros Lakkas; Katerina K Naka
Journal:  Eur Heart J Case Rep       Date:  2019-06-01

Review 10.  Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis.

Authors:  Jakub Sroubek; Vincent Probst; Andrea Mazzanti; Pietro Delise; Jesus Castro Hevia; Kimie Ohkubo; Alessandro Zorzi; Jean Champagne; Anna Kostopoulou; Xiaoyan Yin; Carlo Napolitano; David J Milan; Arthur Wilde; Frederic Sacher; Martin Borggrefe; Patrick T Ellinor; George Theodorakis; Isabelle Nault; Domenico Corrado; Ichiro Watanabe; Charles Antzelevitch; Giuseppe Allocca; Silvia G Priori; Steven A Lubitz
Journal:  Circulation       Date:  2016-01-21       Impact factor: 29.690

View more
  1 in total

1.  Zfhx3 Transcription Factor Represses the Expression of SCN5A Gene and Decreases Sodium Current Density (INa).

Authors:  Marcos Rubio-Alarcón; Anabel Cámara-Checa; María Dago; Teresa Crespo-García; Paloma Nieto-Marín; María Marín; José Luis Merino; Jorge Toquero; Rafael Salguero-Bodes; Juan Tamargo; Jorge Cebrián; Eva Delpón; Ricardo Caballero
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.